Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington’s disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.本發明提供一種特定化學實體，還提供一種醫藥組成物，其包含至少一化學實體和一或多種醫藥上可接受之媒介物，描述一種對患有對抑制KMO活性有反應的特定疾病和障礙的病患之治療方法，所述方法包括向所述病患投予可有效減少所述疾病或障礙的徵象或症狀之至少一定量化學實體，這些疾病包括神經退化性障礙，例如亨廷頓舞蹈症，還描述一種治療方法，其包括投予作為單一活性劑的至少一化學實體，或投予至少一化學實體與一或多種其他治療劑的組合，亦提供一種篩選能夠抑制KMO活性的化合物的方法。
